Logo image of CHRA

CHARAH SOLUTIONS INC (CHRA) Stock Fundamental Analysis

NYSE:CHRA - New York Stock Exchange, Inc. - US15957P3038 - Common Stock - Currency: USD

2.17  +0.08 (+3.83%)

Fundamental Rating

1

Taking everything into account, CHRA scores 1 out of 10 in our fundamental rating. CHRA was compared to 83 industry peers in the Commercial Services & Supplies industry. CHRA may be in some trouble as it scores bad on both profitability and health. CHRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CHRA has reported negative net income.
In the past year CHRA has reported a negative cash flow from operations.
CHRA Yearly Net Income VS EBIT VS OCF VS FCFCHRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

CHRA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHRA Yearly ROA, ROE, ROICCHRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 50 -50 100 -100

1.3 Margins

Looking at the Gross Margin, with a value of 1.79%, CHRA is doing worse than 80.00% of the companies in the same industry.
In the last couple of years the Gross Margin of CHRA has declined.
CHRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24.11%
GM growth 5Y-17.64%
CHRA Yearly Profit, Operating, Gross MarginsCHRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 10 -10 20 -20

More info and screens

2

2. Health

2.1 Basic Checks

CHRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
CHRA has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, CHRA has an improved debt to assets ratio.
CHRA Yearly Shares OutstandingCHRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M
CHRA Yearly Total Debt VS Total AssetsCHRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

2.2 Solvency

CHRA has an Altman-Z score of 0.08. This is a bad value and indicates that CHRA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.08, CHRA is doing worse than 80.00% of the companies in the same industry.
A Debt/Equity ratio of 7.56 is on the high side and indicates that CHRA has dependencies on debt financing.
With a Debt to Equity ratio value of 7.56, CHRA is not doing good in the industry: 91.25% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 7.56
Debt/FCF N/A
Altman-Z 0.08
ROIC/WACCN/A
WACC6.34%
CHRA Yearly LT Debt VS Equity VS FCFCHRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M 100M 150M 200M

2.3 Liquidity

CHRA has a Current Ratio of 1.14. This is a normal value and indicates that CHRA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CHRA (1.14) is worse than 61.25% of its industry peers.
CHRA has a Quick Ratio of 1.09. This is a normal value and indicates that CHRA is financially healthy and should not expect problems in meeting its short term obligations.
CHRA's Quick ratio of 1.09 is in line compared to the rest of the industry. CHRA outperforms 48.75% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.09
CHRA Yearly Current Assets VS Current LiabilitesCHRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CHRA have decreased strongly by -260.00% in the last year.
The Revenue has grown by 146.66% in the past year. This is a very strong growth!
CHRA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.04% yearly.
EPS 1Y (TTM)-260%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-387.5%
Revenue 1Y (TTM)146.66%
Revenue growth 3Y-9.9%
Revenue growth 5Y2.04%
Sales Q2Q%-3.11%

3.2 Future

Based on estimates for the next years, CHRA will show a very negative growth in Earnings Per Share. The EPS will decrease by -347.79% on average per year.
CHRA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.09% yearly.
EPS Next Y-436.41%
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%
EPS Next 5YN/A
Revenue Next Year8.8%
Revenue Next 2Y7.2%
Revenue Next 3Y6.72%
Revenue Next 5Y7.09%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CHRA Yearly Revenue VS EstimatesCHRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CHRA Yearly EPS VS EstimatesCHRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CHRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHRA Price Earnings VS Forward Price EarningsCHRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CHRA Per share dataCHRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80

4.3 Compensation for Growth

CHRA's earnings are expected to decrease with -347.79% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%

More info and screens

2

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 1.26%, CHRA has a reasonable but not impressive dividend return.
The stock price of CHRA dropped by -70.95% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
CHRA's Dividend Yield is a higher than the industry average which is at 2.52.
Compared to an average S&P500 Dividend Yield of 2.38, CHRA's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 1.26%

5.2 History

CHRA is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DP0%
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%
CHRA Yearly Income VS Free CF VS DividendCHRA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M -60M

More info and screens

CHARAH SOLUTIONS INC

NYSE:CHRA (4/3/2023, 8:20:29 PM)

2.17

+0.08 (+3.83%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryCommercial Services & Supplies
Earnings (Last)03-30 2023-03-30
Earnings (Next)05-08 2023-05-08
Inst Owners88.22%
Inst Owner Change-3.06%
Ins Owners66.98%
Ins Owner Change0%
Market Cap7.33M
Analysts48.57
Price Target90.78 (4083.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.26%
Yearly Dividend0.3
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-41.03%
Min EPS beat(2)-58.73%
Max EPS beat(2)-23.34%
EPS beat(4)0
Avg EPS beat(4)-80.85%
Min EPS beat(4)-130.17%
Max EPS beat(4)-23.34%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.78%
Min Revenue beat(2)-4.89%
Max Revenue beat(2)-0.67%
Revenue beat(4)1
Avg Revenue beat(4)0.34%
Min Revenue beat(4)-4.89%
Max Revenue beat(4)8.91%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6257.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-899.19%
EPS NY rev (1m)0%
EPS NY rev (3m)-900.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B 0.31
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-11.7
EYN/A
EPS(NY)-11.31
Fwd EYN/A
FCF(TTM)-24.58
FCFYN/A
OCF(TTM)-23.06
OCFYN/A
SpS94.13
BVpS7.03
TBVpS-25.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.79%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24.11%
GM growth 5Y-17.64%
F-Score1
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 7.56
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 1.09
Altman-Z 0.08
F-Score1
WACC6.34%
ROIC/WACCN/A
Cap/Depr(3y)44.41%
Cap/Depr(5y)46.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-260%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-387.5%
EPS Next Y-436.41%
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%
EPS Next 5YN/A
Revenue 1Y (TTM)146.66%
Revenue growth 3Y-9.9%
Revenue growth 5Y2.04%
Sales Q2Q%-3.11%
Revenue Next Year8.8%
Revenue Next 2Y7.2%
Revenue Next 3Y6.72%
Revenue Next 5Y7.09%
EBIT growth 1Y-259.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-88.36%
EBIT Next 3Y26.32%
EBIT Next 5Y22.98%
FCF growth 1Y-5990.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-931.71%
OCF growth 3YN/A
OCF growth 5YN/A